Loading...

Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571

The Bcr-abl kinase inhibitor STI571 produces clinical responses in most patients with Chronic Myeloid Leukemia (CML); however, development of resistance limits utility. One strategy to overcome STI571 resistance is to decrease the level/activity of Bcr-abl. We reported that disruption of the anti-ap...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang, Zhanxiang, Pelus, Louis M.
Format: Artigo
Language:Inglês
Published: 2008
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2600525/
https://ncbi.nlm.nih.gov/pubmed/19079792
Tags: Add Tag
No Tags, Be the first to tag this record!